-
Loading metrics
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy
- Kerstin Pfister,
- Thomas W. P. Friedl,
- Andreas Hartkopf,
- Franziska Mergel,
- Sophia Huesmann,
- Forca Mehmeti,
- Henning Schäffler,
- Angelina Fink,
- Tatjana Braun,
- Sabine Heublein
x
- Published: November 19, 2025
- https://doi.org/10.1371/journal.pone.0322156